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Abstract
Background: Inhaled steroid resistance is an obstacle to asthma control in asthmatic smokers. The
reasons of this phenomenon are not yet entirely understood. Interaction of drug particles with
environmental tobacco smoke (ETS) could change the aerodynamic profile of the drug through the particle
coagulation phenomenon. Aim of the present study was to examine whether steroid particles interact with
smoke when delivered in the presence of ETS.
Methods: Beclomethasone-hydrofluoralkane (BDP-HFA) pMDI particle profile was studied after a single
actuation delivered in ambient air or in the presence of ETS in an experimental chamber using a light
scattering Optical Particle Counter capable of measuring the concentrations of particle sized 0.3–1.0, 1.1–
2.0, 2.1–3.0, 3.1–4.0, 4.1–5.0, and > 5.1 μm in diameter with a sampling time of one second. The number
of drug particles delivered after a single actuation was measured as the difference between total particle
number after drug delivery and background particle number. Two groups of experiments were carried out
at different ambient background particle concentrations. Two-tail Student's t-test was used for statistical
analysis.
Results: When delivered in ambient air, over 90% of BDP-HFA particles were found in the 0.3–1.0 μm
size class, while particles sized 1.1–2.0 μm and 2.1–3.0 represented less than 6.6% and 2.8% of total
particles, respectively. However, when delivered in the presence of ETS, drug particle profile was modified,
with an impressive decrease of 0.3–1.0 μm particles, the most represented particles resulting those sized
1.1–2.0 μm (over 66.6% of total particles), and 2.1–3.0 μm particles accounting up to 31% of total particles.
Conclusion: Our data suggest that particle interaction between inhaled BDP-HFA pMDI and ETS takes
place in the first few seconds after drug delivery, with a decrease in smaller particles and a concurrent
increase of larger particles. The resulting changes in aerosol particle profile might modify regional drug
deposition with potential detriment to drug efficacy, and represent a new element of steroid resistance in
smokers. Although the present study does not provide any functional or clinical assessment, it might be
useful to advise smokers and non smokers with obstructive lung disease such as asthma or COPD, to avoid
to act inhaled drugs in the presence of ETS in order to obtain the best therapeutic effect.
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Introduction
Suspended particles in aerosol phase are subject to
dynamic changes, mainly due to the process of coagula-
tion, whereby particles collide with one another, and
adhere to form larger particles, due mainly to brownian
motion [1,2]. Collisions with bigger particles generate
larger particles which work as "scavengers" for smaller
particles. The phenomenon is governed by mathematical
equations [3-5], and particle coagulation has been
observed in experimental exposure chambers [6-8], in
indoor settings [3,6,9,10], and in atmospheric environ-
ment research [11]. Particle coagulation takes place very
rapidly, becoming measurable in a few seconds and con-
tinuing up to about a few hours [3-10]. Combustion proc-
esses are the main source of primary and secondary
submicrometric aerosol particles (particles less than 1.0
μm in diameter) [12]. Environmental tobacco smoke
(ETS) is a well studied model of combustion product,
being composed by over 4,000 different chemical sub-
stances [13-15]. Freshly dispersed ETS is composed
mainly by fine particles ranging in diameter 0.02 to 2.0
μm, and displaying a rapid reduction in particle number
with a concurrent increase in mean diameter due to parti-
cle coagulation during the phase of "aging", the process
leading to changes in physical and chemical characterisc-
tics of smoke, which takes place quickly after ETS genera-
tion [3,6,9,10].
ETS is one of the most common cause of indoor pollution
[13], and is a well recognized worldwide respiratory risk
factor [16,17]. Nevertheless, a relevant percentage of asth-
matic subjects have been reported to be current smokers
(35% of asthmatics presenting to emergengy departments
[18], 26% among a series of over 4000 asthma outpatients
in a recent survey [19]), and many non-smoker asthmatics
are exposed to ETS [20].
Although inhaled steroids are the cornerstone of asthma
therapy, their efficacy is dramatically reduced in asthmatic
smokers, compromising asthma control, a phenomenon
called "steroid resistance" [21-24]. So far, possible interac-
tions between drug particles and ETS have not been eval-
uated as a possible explanation for inhaled steroid
resistance. If the drug is delivered in the presence of ETS,
particles might interact with tobacco smoke by modifying
the particle frequency as compared to the original pattern
with an increase in larger particles. Since drug particle size
represents a critical issue for inhaled drug regional depo-
sition, a change in aerodynamic profile could be detri-
mental to its clinical effect [25].
According to pharmaceutical guidelines, inhaled steroids
are studied in ambient air [26], and no concern has yet
been risen about the poor air quality in homes polluted
by ETS where inhaled drugs are frequently actuated. A spe-
cial opportunity of particle interaction is represented by
the huge concentration of submicrometric (less than 1 μm
particles residing in the smoker's lung for up to 3 minutes
after the last cigarette puff (the so-called "residual tobacco
smoke"), if the inhaled drug is actuated shortly thereafter
[27].
The aim of the present report was to investigate if particles
size distribution of beclomethasone-hydrofluoralkane
pressurized metered dose inhaler (BDP-HFA pMDI) is
modified when the pMDI aerosol is delivered in the pres-
ence of ETS.
Materials and methods
A series of experiments was carried out by measuring BDP-
HFA pMDI (Qvar, 3 M Health Care, Ltd, Loughborough,
UK) particle size distribution in ambient air (background
room air) or in the presence of ETS (background room air
additioned with tobacco smoke produced by consuming
a smouldering cigarette for 0.5 cm from the tip). The opti-
cal particle counter based on real time laser diffraction
(model 9012, Metone, Grants Pass, USA) was used, capa-
ble of measuring the concentration of particles in the
range size of 0.3–1.0, 1.1–2.0, 2.1–3.0, 3.1–4.0, 4.1–5.0,
and > 5.1 μm with a sampling time of 1 second [27]. The
analyser was placed inside a 6.5 m3 acrylic chamber along
with temperature and relative humidity control devices,
and with the inner surface coated with antistatic paint to
avoid losses of particles due to electrostatic charges. A
scheme of the experimental setting is shown in Figure 1.
The chamber temperature ranged between 21 and 22°C,
while relative humidity beteween 45 and 55%. The study
was carried out by delivering a single actuation of BDP-
HFA pMDI in two different settings: a) in the presence of
ambient air, and b) in the presence of ETS. All data were
compensated for coincidence losses, concentration reduc-
tion caused by particle sedimentation and adsorption,
and for relative humidity interference. Air mixing was pro-
vided by two fixed speed fans located inside the box.
Chamber air was fully changed after each test. For each
experiment, BDP-HFA pMDI particle number was calcu-
lated by subtracting the background particle concentra-
tion (mean of the last 100 measurements before drug
delivery) from the mean of first 100 measurements of
total particles number recorded after drug delivery.
Two different groups of experiments were carried out at
different times using the same laboratory setting, but with
a different serial number of the same particle counter
model, and at different ambient background particle con-
centrations. Background particle concentrations after ETS
injection were similar in the different experiments. The
first group of experiments was done in triplicate (three
ambient and three ETS tests), while the second one wasRespiratory Research 2009, 10:48 http://respiratory-research.com/content/10/1/48
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done in quadruplicate. Statistical data analysis was per-
formed with two-tail Student's t-test.
Results
An explanatory picture of real time measurement before
and after the drug delivery in ambient air is shown in Fig-
ure 2, left side, representing the graphical data of test #1,
belonging to the first group of experiments (test group 1):
immediately after BDP-HFA pMDI actuation the number
of particles increased significantly for every particle size
(0.3–1.0 μm to > 5.1 μm in diameter) with a prevalence
of particles sized 0.3–1.0 μm.
Table 1 shows the details of the data of this group of tests:
an increase in the number of particles over the back-
ground was observed for every aerodynamic size class
after drug delivery, with a mean ± SD increase in p/l after
drug delivery of 19277 ± 2292, 1423 ± 249, 593 ± 156, 39
± 45, 18 ± 32, and 21 ± 43 for particles sized 1.1–2.0, 2.1–
3.0, 3.1–4.0, 4.1–5.0, and > 5.1 μm, respectively (pooled
data of the 3 tests).
Background particle concentrations were stable during the
tests, with a mean ± SD particle concentration (pooled
data) of 1545 ± 163, 51 ± 35, 58 ± 42, 30 ± 34, 13 ± 14
and 35 ± 31 p/l for the same size classes, respectively.
Figure 3 shows the mean ± SD particle frequency of BDP-
HFA pMDI: when delivered in ambient air, 90.20 ± 0.97%
of the delivered drug was represented by 0.3–1.0 μm par-
ticles, while particles 1.1–2.0 and 2.1–3.0 accounted for
6.66 ± 0.54% and 2.78 ± 0.40% of total particles, respec-
tively, with particles over 3.1 μm in diameter accounting
for less than 1%.
When the same set of experiments was carried out with
BDP-HFA pMDI delivered in the presence of ETS, the dis-
tribution of the particle diameter changed, with a signifi-
cant decrease of particle number for particle sized 0.3–1.0
μm, as compared to background particle concentrations
(Fig. 2, right side, representing the graphical data of test
#4). By contrast, an excess number of larger particles was
recorded as compared to the amount of particles meas-
ured in ambient air.
As reported in Table 1, pooled data of the 3 test (#4 – #6)
performed in the presence of ETS showed a mean ± SD
decrease of -3920 ± 5330 p/l for 0.3–1.0 μm particles,
The figure represents a scheme of the experimental setting Figure 1
The figure represents a scheme of the experimental setting. 1: speed fan. 2: optical particle counter. 3: computer. 4: 
opening for pMDI drug delivery. T: temperature sensor. RH: relative humidity sensor.Respiratory Research 2009, 10:48 http://respiratory-research.com/content/10/1/48
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Particle/liter counts (0.3–1.0 μm through > 5 μm) after a single actuation of BDP-HFA pMDI in ambient air (left) and ETS  (right) Figure 2
Particle/liter counts (0.3–1.0 μm through > 5 μm) after a single actuation of BDP-HFA pMDI in ambient air 
(left) and ETS (right). Particle count was measured with a sampling time of one second. Continuous red lines indicate mean 
particle count of the background and after BDP-HFA pMDI shot. The sign "delta" shows the gradient in particle count after 
drug delivery(means of 100 counts after delivery less means of 100 counts before delivery). When delivered in ETS, a net 
decrease in the number of 0.3–1.0 μm particles occurred as compared to delivery in ambient air, while a concurrent increase 
in the number of larger particles was observed.Respiratory Research 2009, 10:48 http://respiratory-research.com/content/10/1/48
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Table 1: Test group 1 particle gradient compared to background after a single actuation of BDP-HFA PMDI: decrease in 
submicrometric and increase in larger particle number in the presence of ETS.
Particle diameter 0.3–1.0 μm 1.1–2.0 μm2 . 1 – 3 . 0   μm3 . 1 – 4 . 0   μm 4.1–5.0 μm>  5 . 1  μm
Ambient Air
Test # 1 19538 ± 2373 1421 ± 251 632 ± 162 58 ± 45 17 ± 35 12 ± 45
Test # 2 19759 ± 1355 1343 ± 191 504 ± 107 21 ± 46 11 ± 30 30 ± 42
Test # 3 18536 ± 849 1505 ± 178 643 ± 128 38 ± 41 25 ± 30 20 ± 42
Pooled data of 3 tests 19277 ± 2292 1423 ± 249 593 ± 156 39 ± 45 18 ± 32 21 ± 43
ETS
Test # 4 -4430 ± 4895 4523 ± 1186 1968 ± 668 108 ± 67 25 ± 38 9 ± 40
Test # 5 -3941 ± 5193 4655 ± 1228 2039 ± 741 106 ± 72 24 ± 41 16 ± 49
Test # 6 -3389 ± 5481 4546 ± 9367 2412 ± 4375 103 ± 172 40 ± 52 26 ± 38
Pooled data of 3 tests -3920 ± 5330* 4575 ± 5522* 2140 ± 2584* 106 ± 115* 30 ± 44* 17 ± 43
ETS = Environmental Tobacco Smoke; BDP-HFA pMDI = beclomethasone-hydrofluoralkane pressurized metered dose inhaler; μm = micrometers.
Values are number of particles/liter (mean ± SD).
*P < 0.001 as compared to pooled data in clean air for the same particle diameter.
Tests group 1 Figure 3
Tests group 1. Particle frequency of BDP-HFA pMDI delivered in ambient air (open columns) and in ETS (black columns). 
Particles sized 0.3–1.0 μm, which predominated in ambient air, were no longer measurable in ETS, particles in the range of 1.0 
to 3.0 μm in diameter being mostly represented.Respiratory Research 2009, 10:48 http://respiratory-research.com/content/10/1/48
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while an increase of 4575 ± 5522, 2140 ± 2584, 106 ±
115, 30 ± 44, and 17 ± 43 was observed for particle sized
1.1–2.0, 2.1–3.0, 3.1–4.0, 4.1–5.0, and > 5.1 μm, respec-
tively. When compared to the tests in ambient air, the
number of drug particle delivered in the presence of ETS
was statistically significant for all the particle diameters,
except for particles over 5.1 μm in size.
ETS particle concentrations were similar in the three dif-
ferent tests, with a mean ± SD particle concentration
(pooled data) of 624511 ± 3218, 14542 ± 854, 4239 ±
478, 112 ± 43, 27 ± 24, and 34 ± 28 p/l for particle diam-
eters of 0.3–1.0, 1.1–2.0, 2.1–3.0, 3.1–4.0, 4.1–5.0, and >
5.1 μm, respectively. The exceedingly high prevalence of
submicrometric particles with a very low number of
coarse particles is consistent with the particle composition
of ETS aerosol assessed by previous studies [3,6,9,10].
As shown in Figure 3, the mean ± SD particle frequency of
BDP-HFA pMDI delivered in ETS (black bars) was very dif-
ferent as compared to the particle profile of the drug deliv-
ered in the presence of ambient air: 0.3–1.0 μm particles
disappeared, while particles sized 1.1–2.0 μm and 2.1–3.0
μm predominated with a mean ± SD percentage of 66.62
± 2.92 and 31.16 ± 2.97. Particles sized 3.1–4.0 μm
accounted for a mean ± SD of 1.54 ± 0.09%, while parti-
cles 4.1–5.0 and > 5.1 μm in diameter represented less
than 1% of total particles.
A similar set of experiments (test group 2), was carried at
a different time, with the same model of a particle counter
of a different serial number, and with different back-
ground air conditions (Table 2). Four test were carried out
both for actuations in ambient air and in ETS. When BDP-
HFA pMDI was delivered in ambient air, an increase in the
number of particles over the background was observed for
every aerodynamic size class after drug delivery, with a
mean ± SD increase in p/l (pooled data of test #7 – # 10)
of 24093 ± 211, 894 ± 22, 89 ± 5, 10 ± 4, 2 ± 2, and 1 ± 1
p/l, for particles sized 1.1–2.0, 2.1–3.0, 3.1–4.0, 4.1–5.0,
and > 5.1 μm, respectively.
Background particle concentrations were similar during
the experimental session, with a mean ± SD of 94479 ±
1485, 517 ± 105, 68 ± 39, 12 ± 15, 5 ± 10, 4 ± 9, for par-
ticles sized 1.1–2.0, 2.1–3.0, 3.1–4.0, 4.1–5.0, and > 5.1
μm, respectively.
Figure 4 shows the mean ± SD particle frequency of BDP-
HFA pMDI of test group 2 experiments when delivered in
ambient air (open bars): the data were similar to test
group 1 findings, with a predominance of 0.3–1.0 μm par-
ticles which represented 90.20 ± 0.97% of total particles,
while particles 1.1–2.0 and 2.1–3.0 accounted for 6.66 ±
0.54% and 2.78 ± 0.40%, respectively, with particles over
3.1 μm in diameter accounting for less than 1%.
Tests group 2 Figure 4
Tests group 2. Particles frequency of BDP-HFA pMDI delivered in ambient air (open columns) and in ETS (black columns). 
Particles sized 0.3–1.0 μm, which predominated in ambient air, were again no longer measurable in ETS, particles in the range 
of 1.0 to 3.0 μm in diameter being mostly represented.Respiratory Research 2009, 10:48 http://respiratory-research.com/content/10/1/48
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The pooled data of tests #11–# 14, carried out in the pres-
ence of ETS, showed a net decrease in the number of 0.3–
1.0  μm particles (-2412 ± 188), while a mean ± SD
increase of 1609 ± 46, 139 ± 9, 11 ± 4, 2 ± 2, 1 ± 2 p/l was
observed for particle sized 1.1–2.0, 2.1–3.0, 3.1–4.0, 4.1–
5.0, and > 5.1 μm, respectively (Table 2). When compared
to the tests in ambient air, the number of drug particle
delivered in the presence of ETS was significantly different
for particles sized 0.3–1.0, 1.1–2.0, and 2.1–3.0 μm.
ETS particle concentrations were similar in the 4 different
tests, with a mean ± SD particle concentration (pooled
data) of 584934 ± 2764, 2422 ± 214, 158 ± 58, 25 ± 24, 9
± 13, and 10 ± 13 p/l, for particle diameters of 0.3–1.0,
1.1–2.0, 2.1–3.0, 3.1–4.0, 4.1–5.0, and > 5.1 μm, respec-
tively.
As shown in Figure 4 (black bars), the mean ± SD particle
frequency of BDP-HFA pMDI delivered in ETS changed as
compared to the particle profile of the drug delivered in
the presence of ambient air: 0.3–1.0 μm particles disap-
peared, while particles sized 1.1–2.0 μm and 2.1–3.0 μm
predominated with a mean (SD) percentage of 92.07 ±
0.1 and 7,93 ± 0.3, respectively, while particles larger that
3.1 μm representing less than 1% of total particles.
Discussion
Our results indicate that delivery in the presence of ETS
can affect pMDI steroid particle size distribution with a
shift towards larger particle size taking place in a few sec-
onds. In the two groups of experiments with different
ambient backgrounds the particle frequency in ETS
showed the disappearance of particles sized 0.3–1.0 μm in
diameter, with an increase mainly in 1.1–2.0 and 2.1–3.0
μm particles.
We choose extrafine HFA formulation BDP because it is a
widely used inhaled steroid and because it is the only
inhaled corticosteroid included in the list of essential
drugs of the World Health Organization [28]. Bronchial
deposition of drugs depends on particle diameter, the
smaller the particles, the easier they reach the most
peripheral regions of the lung [29-31]. Due to the
extrafine particle profile of BDP-HFA pMDI, the shift
towards larger size class distribution did not cause an
increase in the percentage of particles sized > 5.1 μm, thus
fully preserving the ability of the drug to reach the lung,
only particles with diameter < 6.0 μm being considered
suitable for this behaviour [29-31].
Table 2: Test group 2 particle gradient compared to background after a single actuation of BDP-HFA PMDI: decrease in 
submicrometric and increase in larger particle number in the presence of ETS.
Particle diameter 0.3–1.0 μm 1.1–2.0 μm2 . 1 – 3 . 0   μm 3.1–4.0 μm 4.1–5.0 μm > 5.1 μm
Ambient Air
Test # 7 23419 ± 173 908 ± 18 100 ± 5 9 ± 5 2 ± 1 0 ± 1
Test # 8 25245 ± 210 906 ± 20 80 ± 5 7 ± 2 2 ± 2 1 ± 1
Test # 9 24617 ± 280 903 ± 31 80 ± 6 9 ± 4 2 ± 2 1 ± 1
Test # 10 23092 ± 179 858 ± 19 98 ± 5 13 ± 4 2 ± 2 2 ± 2
Pooled data of 4 tests 24093 ± 211 894 ± 22 89 ± 5 10 ± 4 2 ± 2 1 ± 1
ETS
Test # 11 -2633 ± 196 1574 ± 41 140 ± 9 11 ± 3 2 ± 2 0 ± 1
Test # 12 -2623 ± 206 1505 ± 50 136 ± 10 10 ± 3 1 ± 1 1 ± 1
Test # 13 -2180 ± 161 1604 ± 44 127 ± 8 16 ± 5 3 ± 2 3 ± 2
Test# 14 -2212 ± 189 1751 ± 49 151 ± 8 7 ± 4 2 ± 2 1 ± 1
Pooled data of 4 tests -2412 ± 188* 1609 ± 46* 139 ± 9* 11 ± 4 2 ± 2 1 ± 2
ETS = Environmental Tobacco Smoke; BPD-HFA pMDI = beclometasone-hydrofluoroalkane pressurized metered dose inhaler; μm = micrometers.
Values are number of particles/liter (mean ± SD).
*P < 0.001 as compared to pooled data in ambient air for the same particle diameterRespiratory Research 2009, 10:48 http://respiratory-research.com/content/10/1/48
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The growth in particle size might change drug deposition
in the small airways, which are involved in inflammation
processes and bronchoconstriction both in asthma and in
COPD, even though such a principle may not be working
for other drugs. In fact, Usmani and co-workers reported
that larger particles were more efficacious than smaller
particles for the beta-agonist albuterol [30]. Interactions
with ETS regard mainly smokers, because of the presence
of residual tobacco smoke which can persist in their lung
for several minutes aftre the last puff [27], and because of
their condition as a category exposed to their own ETS.
However, also non smokers are subject to the risk of tak-
ing altered inhaled drugs due to ETS, because smoking in
the home is still the major cause of exposure to second-
hand smoke, especially in children [32].
Although active and passive smoking are regarded as
important risk factors for asthma exacerbations, and in
spite of the fact that the issue of poor asthma control in
current smokers is drawing attention also in the primary
care setting [19,33], no special advice to avoid interfer-
ence of tobacco smoke when using inhaled drugs is
reported in asthma guidelines and reccomendations
[25,33-39]. Only the paragraph devoted to pentamidine
aerosol delivery in the British Society Nebulizer Study
Group Report recommends that "patients should not
smoke cigarettes for two hours before treatment" [34].
However, if particle interaction can be a problem for asth-
matic smokers, it is even more important for patients with
chronic obstructive pulmonary disease (COPD), since
about 50% of COPD patients on inhaled drug therapy are
current smokers [39,40]. Drug prescription leaflets of the
most used inhaled drugs do not give any advice to patients
regarding neither the timing of actuation in relation to the
last puff of cigarette, nor the pollution level of the room
where the drugs are delivered.
The results obtained with the real time laser-operated ana-
lyser were consistent and repeatable. However this tech-
nique has some limitations, such as the possibility of
interferences due to coincidence losses in particle count at
high particle concentrations: therefore, data for particles
sized 0.3–1.0 μm in diameter were corrected according to
a proper equation. In addition, our data showed a concur-
rent increase in the number of particles with larger size
class, a result difficult to explain by a technical artifact.
Another limitation of the optical particle counter technol-
ogy is that it measures only particle number and size,
without characterizing the kind of particles measured and
determining their mass. The results are therefore only sug-
gestive of particle coagulation. Further studies with differ-
ent methodologies such as Andersen cascade impactor
and Scanning Electron Microscopy technology are needed
to provide such an information and confirm the presence
of the phenomenon [26]. As for temperature and relative
humidity, ETS addition to the chamber did not alter these
parameters as compared to ambient air experiments,
probably because of the very limited amount of smoke
inflated into the test chamber (0.5 cm of a smouldering
cigarette). Other physical processes affecting aerosol
dynamics, like charge effects of ETS particles and hygro-
scopic properties of inhaled drug particles could play a
role in the observed findings, and deserve suitable
research [2].
BDP-HFA pMDI particle profile showed small differences
in the two different tests groups carried out at different
times in ambient air: particle frequency was 90.2%, 6.7%,
and 2.8% in test group 1, and 96.2%, 3.5%, and 0.4% in
test group 2, for particles sized 0.3–1.0, 1.1–2.0, and 2.1–
3.0 μm in diameter, respectively (see Figure 3 and 4). The
differences were more relevant for drug delivery in ETS,
with a particle frequency of 66.6%, 31.2%, and 1.5%, and
of 92.2%, 7.9% and 0.63% for particles sized 1.1–2.0,
2.1–3.0, and 3.1–4.0 μm in diameter, in two test groups,
respectively. Such discrepancies could be explained
because two different analyzers were used, and due to the
different ambient air background.
It should be underlined that, although in the presence of
ETS the aerodynamic profile of BDP-HFA pMDI particles
was deeply altered, the "load" of particles ranging
between 0.3 and 3.0 μm in diameter, altogether, did not
change when comparing ambient air vs  ETS profile,
accounting for over 97% of total particles, suggesting only
minor changes in overall regional deposition of the drug
[29-31].
Although much higher than the ambient air counterpart,
the mean levels of background submicrometric particle
concentrations used in the experiments with ETS repre-
sent real world indoor concentrations which can be cur-
rently encountered in ETS polluted places, reaching levels
of several hundred thousand particles per liter
[2,3,9,10,27].
The possibility of spontaneous "self coagulation" of ETS
deserve a comment. A particle size increase between 20
and 50% along with a concurrent reduction in total parti-
cle number were reported by Morawska and co-workers
during the first 30 to 60 minutes after of ETS production
[6], while Ning et al. showed a drop from ~1 × 105 to ~6
× 104/cm3 in total ETS particles in the first 15 minutes
since generation [10]. In our experiments no detectable
change in particle number was observed in ETS back-
ground during the 100 seconds preceding drug delivery,
thus excluding such a phenomenon to explain the rapid
drop in submicrometric particles we observed just after
the pMDI actuations.Respiratory Research 2009, 10:48 http://respiratory-research.com/content/10/1/48
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Another issue to be discussed is the rapidity of particle
interaction. In a recent study, Seipenbush and co-workers
were able to demonstrate that the injection of 0.2 μm
sebacate droplets into a background aerosol of platinum
nanoparticles induced a heterogeneous coagulation proc-
ess measurable in the first 4 minutes of interaction [8].
The authors carried out chemical and morphological anal-
ysis of collected particles, and concluded that nanoparti-
cles coagulate very rapidly after the injection of sebacate
particles, in an experimental setting which is very similar
to ours.
Conclusion
In summary, our data showed that the particle profile of
the inhaled steroid BDP-HFA pMDI is altered when the
drug is delivered in the presence of ETS. Although further
studies are needed to confirm these findings, and
although the present study does not provide any func-
tional or clinical assessment, the results are relevant to the
phenomenon of steroid resistance [22].
Smoking has been shown to impair the clinical response
to systemic steroids through biochemical mechanisms
affecting steroid pharmacodynamics at the cellular level
[41,42]. Our data suggest that particle interaction and
growth should be taken into account as another mecha-
nism contributing to the reduced clinical efficacy of
inhaled steroid medications in smokers, adding a new
piece of evidence. In view of the present findings, it seems
reasonable that smokers with obstructive lung disease
such as asthma or COPD should be advised, in addition
to stop smoking, to act their inhaled drugs in ETS-free
ambient air, and far from the last cigarette puff, in order
to obtain the best therapeutical effect. Likewise, also non-
smokers should receive instructions about the influence
of indoor ETS pollution on their inhaled medications.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
GI and AR conceived the study, carried out the particle
interaction studies, and performed the statistical analysis.
CDM, RM, GN and RB participated in the design of the
study, and helped to draft the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This work was financially supported by Fondazione IRCCS Istituto Nazion-
ale dei Tumori, Milan, Italy.
References
1. Whitby KT: The physical characteristics of sulfur aerosol.
Atmos Environ 1978, 12:135-59.
2. Hinds WC: Aerosol Technology: Properties, Behavior, and
Measurement of Airborn Particles.  New York:Wiley; 1999. 
3. Nazaroff WW, Cass GR: Mathematical modeling of indoor aer-
osol dynamics.  Environ Sci Technol 1989, 23:157-166.
4. Jung CH, Kim YP, Lee KW: Simulation of the influence of coarse
mode particles on the properties of fine mode particles.  Aer-
osol Science 2002, 33:1201-1216.
5. Park SH, Kruis FE, Lee KW, Fissan H: Evolution of Particle Size
Distributions due to Turbulent and Brownian coagulation.
Aerosol Sci Technolog 2002, 36:419-432.
6. Morawska L, Jarmiska M, Bofinger ND: Size characteristics and
ageing of environmental tobacco smoke.  Sci Total Environ 1997,
196:43-55.
7. Oberdörster G, Finkelstein JN, Johnston C, Gelein R, Cox C, Baggs
R, Elder AC: Acute Pulmonary Effects of Ultrafine Particles in
Rats and Mice.  Cambridge (MA): Health Effects Institute; 2000. 
8. Seipenbusch M, Binder A, Kasper G: Temporal Evolution of Nan-
oparticle Aerosols in Workplace Exposure.  Ann Occup Hyg.
2008, 52(8):707-716.
9. Klepeis NE, Apte MG, Gundel LA, Sextro RG, Nazaroff WW: Deter-
mining size-specific emission factors for environmental
tobacco smoke particles.  Aerosol Science Technol 2003,
37:780-790.
10. Ning Z, Cheung CS, Fu J, Liu MA, Schell MA: Experimental study
of environmental tobacco smoke particles under actual
indoor environment.  Sci Total Environ 2006, 367:822-830.
11. Zhu Y, Hinds WC, Kim S, Sioutas C: Concentration and size dis-
tribution of ultrafine particle near a major highway.  J Air
Waste Manag Assoc 2002, 52:1032-1042.
12. Lighty JS, Veranth JM, Sarofim AF: Combustion aerosols: factors
governing their size and composition and implications to
human health.  J Air Waste Manag Assoc.  2000, 50(9):1565-1618.
13. Repace JL, Lowrey AH: Indoor air pollution, tobacco smoke,
and public health.  Science.  1980, 208(4443):464-472.
14. Nelson PR, Kelly SP, Conrad FW: Studies of environmental
tobacco smoke generated by different cigarettes.  J Air &
Waste Manage Assoc 1998, 48:336-344.
15. Clearing the Smoke: Assessing the Science Base for Tobacco
Harm Reduction.  New York: National Academy Press. Washing-
ton; 2001. 
16. US Department of Health and Human Services: Smoking and
tobacco control. National CancerInstitute (NCI): Health
effects of exposure to environmental tobacco smoke.  In The
Report of theCalifornia Environmental Protection Agency. Monograph N°10
National Institutes of Health. Bethesda (MD); 1999. 
17. World Health Organization: International Agency For Research
On Cancer.  In IARC Monographs on the Evaluation of Carcinogenic
Risks to Humans Volume 83. Tobacco Smoke and Involuntary Smoking.
Lyon; 2002. 
18. Silverman RA, Boudreaux ED, Woodruff PG, Clark S, Camargo CA:
Cigarette Smoking Among Asthmatic Adults Presenting to
64 Emergency Departments.  Chest.  2003, 123(5):1472-1479.
19. Molimard M, Le Gros V: Impact of patient-related factors on
asthma control.  J Asthma.  2008, 45(2):109-113.
20. Eisner MD, Katz PP, Yelin EH, Hammond SK, Blanc PD: Measure-
ment of environmental tobacco smoke exposure among
adults with asthma.  Environ Health Perspect. 2001,
109(8):809-814.
21. Pedersen B, Dahl R, Karlstrom R, Peterson CG, Venge P: Eosinophil
and neutrophil activity in asthma in a one-year trial with
inhaled budesonide. The impact of smoking.  Am J Respir Crit
Care Med 1996, 153(51519-1529 [http://ajrccm.atsjournals.org/cgi/
content/abstract/153/5/1519].
22. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP,
Thomson NC: Influence of cigarette smoking on inhaled corti-
costeroid treatment in mild asthma.  Thorax.   2002,
57(3):226-230.
23. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF,
Thomson NC: Efficacy of low and high dose inhaled corticos-
teroid in smokers versus non-smokers with mild asthma.
Thorax.  2005, 60(4):282-287.
24. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R,
Craig TJ, Deykin A, DiMango E, Fish JE, Ford JG, Israel E, Kiley J, Kraft
M, Lemanske RF Jr, Leone FT, Martin RJ, Pesola GR, Peters SP, Sork-
ness CA, Szefler SJ, Wechsler ME, Fahy JV, National Heart Lung and
Blood Institute's Asthma Clinical Research Network: Smoking
affects response to inhaled corticosteroids  or leukotrienePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Respiratory Research 2009, 10:48 http://respiratory-research.com/content/10/1/48
Page 10 of 10
(page number not for citation purposes)
receptor antagonists in asthma.  Am J Respir Crit Care Med 2007,
175:783-90.
25. ERS Task Force: European Respiratory Society Guidelines on
the use of nebulizers.  Eur Respir J.  2001, 18(1):228-242.
26. Guidance for Industry: Metered Dose Inhaler (MDI) and Dry
Powder Inhaler (DPI) Drug Products Chemistry, Manufac-
turing, and Controls Documentation.  1998 [http:www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryIn formation/
Guidances/ucm070573.pdf]. U.S. Department of Health and Human
Services Food and Drug Administration Center for Drug Evaluation
and Research (CDER)
27. Invernizzi G, Ruprecht A, De Marco C, Paredi P, Boffi R: Residual
tobacco smoke: measurement of its washout time in the
lung and of its contribution to environmental tobacco
smoke.  Tob Control.  2007, 16(1):29-33.
28. WHO: Model List of Essential Medicines.  15th edition. 2007
[http://www.who.int/medicines/publications/
08_ENGLISH_indexFINAL_EML15.pdf].
29. Leach CL, Davidson PJ, Boudreau RJ: Improved airway targeting
with the CFC-free HFA-beclomethasone metered-dose
inhaler compared with CFC-beclomethasone.  Eur Respir J.
1998, 12(6):1346-1353.
30. Usmani OS, Biddiscombe MF, Barnes PJ: Regional lung deposition
and bronchodilator response as a function of beta2-agonist
particle size.  Am J Respir Crit Care Med.  2005, 172(12):1497-504.
31. Svartengren M, Anderson M, Bylin G, Philipson K, Camner P:
Regional deposition of 3.6-micron particles and lung function
in asthmatic subjects.  J Appl Physiol.  1991, 71(6):2238-2243.
32. Ritchie D, Amos A, Phillips R, Cunningham-Burley S, Martin C:
Action to achieve smoke-free homes- an exploration of
experts' views.  BMC Public Health. 2009, 9:112.
33. Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, Moffat
M, Versnel J, Shanahan ER, Hillyer EV, Tunsa A, Bjermer L: Achieving
asthma control in practice: understanding the reasons for
poor control.  Respir Med.  2008, 102(12):1681-1693.
34. British Society Nebulizer Project Group: Guidelines.  Thorax 1997,
52(Suppl 2):S4-S16.
35. Sestini P, Cappiello V, Aliani M, Martucci P, Sena A, Vaghi A, Canessa
PA, Neri M, Melani AS: Prescription Bias and Factors Associ-
ated with Improper Use of Inhalers.  J Aerosol Med. 2006,
19(2):127-136.
36. National Heart, Lung, and Blood Institute: National Asthma Edu-
cation and Prevention Program.  Expert Panel Report 3: Guidelines
for the Diagnosis and Management of Asthma Full Report 2007 [http://
www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf].
37. Global Strategy for Asthma Management and Prevention
Global Initiative for Asthma (GINA) 2008 [http://www.ginasthma.org/
Guidelineitem.asp??l1=2&l2=1&intId=60].
38. Diette GB, McCormack MC, Hansel NN, Breysse PN, Matsui EC:
Environmental Issues in Managing Asthma.  Respir Care.  2008,
53(5):602-615.
39. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, on
behalf of the ISOLDE Study Group: Prednisolone response in
patients with chronic obstructive pulmonary disease: results
from the ISOLDE study.  Thorax 2003, 58:654-658.
40. GOLD: Global Strategy for Diagnosis, management, and Pre-
vention of COPD.  2008 [http://www.goldcopd.org/Guidelinei
tem.asp?l1=2&l2=1&intId=2003].
41. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W,
Thomson NC: Cigarette smoking impairs the therapeutic
response to oral corticosteroids in chronic asthma.  Am J
Respir Crit Care Med. 2003, 168(11):1308-1311.
42. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A,
Hayashi S, Adcock IM, Hogg JC, Barnes PJ: Decreased histone
deacetylase activity in chronic obstructive pulmonary dis-
ease.  N Engl J Med.  2005, 352(19):1967-1976.